.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,415,345

« Back to Dashboard

Claims for Patent: 8,415,345

Title:Benzene sulfonamide thiazole and oxazole compounds
Abstract: The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
Inventor(s): Adjabeng; George (Durham, NC), Adams; Jerry Leroy (Collegeville, PA), Dickerson; Scott Howard (Durham, NC), Hornberger; Keith (Mount Sinai, NY), Johnson; Neil W. (Collegeville, PA), Kuntz; Kevin (Durham, NC), Petrov; Kimberly (Durham, NC), Ralph; Jeffrey M. (Collegeville, PA), Rheault; Tara Renae (Durham, NC), Schaaf; Gregory (Durham, NC), Stellwagen; John (Durham, NC), Tian; Xinrong (Collegeville, PA), Uehling; David E. (Durham, NC), Waterson; Alex G. (Durham, NC), Wilson; Brian (Durham, NC)
Assignee: Glaxo SmithKline LLC (Philadelphia, PA)
Application Number:12/991,004
Patent Claims: 1. A compound of formula (I) ##STR00627## wherein: a is 0, 1, 2 or 3; each R.sup.1 is the same or different and is independently selected from halo, alkyl, haloalkyl, --OR.sup.6, --CO.sub.2R.sup.6, --NR.sup.6R.sup.7, and --CN; Ring A is selected from C.sub.3-6cycloalkyl, phenyl, 5-6 membered heterocycle and 5-6 membered heteroaryl, said heterocycle and said heteroaryl each having 1 or 2 heteroatoms selected from N, O and S; each of Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 is CH, C--R.sup.2 or N, wherein not more than one of Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 is N; each R.sup.2 is the same or different and is independently selected from halo, alkyl, haloalkyl, and --OR.sup.6; W is selected from --O-- and --S--; R.sup.3 is selected from H, alkyl, haloalkyl-, -alkylene-OH, --NR.sup.6R.sup.7, --C.sub.3-6cycloalkyl, -alkylene-C(O)--OH, -alkylene-NH.sub.2, and Het; wherein said R.sup.3C.sub.3-6cycloalkyl is optionally substituted with 1 or 2 substituents which are the same or different and are independently selected from halo, C.sub.1-3alkyl, haloC.sub.1-3alkyl, OH, O--C.sub.1-3alkyl, oxo, S(C.sub.1-3alkyl), SO.sub.2, NH.sub.2, N(H)C.sub.1-3alkyl and N(C.sub.1-3alkyl).sub.2; Het is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N, O and S and optionally substituted with 1 or 2 substituents which are the same or different and are each independently selected from halo, C.sub.1-3alkyl, haloC.sub.1-3alkyl, O--C.sub.1-3alkyl, C.sub.1-3alkylene-O--C.sub.1-3alkyl, OH, C.sub.1-3alkylene-OH, oxo, SO.sub.2(C.sub.1-3alkyl), C.sub.1-3alkylene-SO.sub.2(C.sub.1-3alkyl), NH.sub.2, N(H)C.sub.1-3alkyl, N(C.sub.1-3alkyl).sub.2, CN, and --CH.sub.2CN; R.sup.4 is selected from H, alkyl, haloalkyl, alkenyl, --OR.sup.6, --R.sup.5--OR.sup.6, --R.sup.5--CO.sub.2R.sup.6, --R.sup.5--SO.sub.2R.sup.6, --R.sup.5--Het, --R.sup.5--C(O)--Het, --N(H)R.sup.8, --N(CH.sub.3)R.sup.8, and --R.sup.5--NR.sup.6R.sup.7; each R.sup.5 is the same or different and is independently C.sub.1-4olkylene; each R.sup.6 and each R.sup.7 is the same or different and is independently selected from H, alkyl, haloalkyl, --C(O)-alkyl, and --C(O)-cycloalkyl; R.sup.8 is selected from H, alkyl (optionally substituted by --OH), haloalkyl, C.sub.3-6cycloalkyl, --R.sup.5--C.sub.3-6cycloalkyl, Het.sup.2, --R.sup.5--Het.sup.2, --R.sup.5--OR.sup.6, --R.sup.5--O--R.sup.5--OR.sup.6, --R.sup.5--C(O).sub.2R.sup.6, --R.sup.5--C(O)NR.sup.6R.sup.7, --R.sup.5--N(H)C(O)--R.sup.6, --R.sup.5--N(H)C(O)--R.sup.5--OR.sup.6, --R.sup.5--N(H)C(O).sub.2--R.sup.6, --R.sup.5--NR.sup.6R.sup.7, --R.sup.5--S(O).sub.2R.sup.6, --R.sup.5--CN, and --R.sup.5--N(H)S(O).sub.2R.sup.6; wherein said R.sup.8C.sub.3-6cycloalkyl is optionally substituted with 1 or 2 substituents which are the same or different and are independently selected from halo, C.sub.1-3alkyl, haloC.sub.1-3alkyl, OH, O--C.sub.1-3alkyl, oxo, S(C.sub.1-3alkyl), SO.sub.2(C.sub.1-3alkyl), NH.sub.2, N(H)C.sub.1-3alkyl and N(C.sub.1-3alkyl).sub.2, and N(H)SO.sub.2C.sub.1-3alkyl; and Het.sup.2 is a 4-6 membered heterocycle having 1 or 2 heteroatoms selected from N, O and S and optionally substituted with 1, 2, 3, 4 or 5 C.sub.1-3alkyl or 1 or 2 substituents which are the same or different and are each independently selected from halo, C.sub.1-3alkyl, haloC.sub.1-3alkyl, O--C.sub.1-3alkyl, C.sub.1-3alkylene-O--C.sub.1-3alkyl, OH, C.sub.1-3alkylene-OH, oxo, SO.sub.2(C.sub.1-3alkyl), C.sub.1-3alkylene-SO.sub.2(C.sub.1-3alkyl), NH.sub.2, N(H)C.sub.1-3alkyl, N(C.sub.1-3alkyl).sub.2, N(H)SO.sub.2C.sub.1-3alkyl, C(O)(C.sub.1-3alkyl), CO.sub.2(C.sub.1-4alkyl), CN, and --CH.sub.2CN; and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1, wherein each R.sup.1 is the same or different and is independently selected from halo, alkyl, haloalkyl, and --OR.sup.6.

3. The compound according to claim 1, wherein Ring A is phenyl, 5-6 membered heterocycle or 5-6 membered heteroaryl.

4. The compound according to claim 1, wherein each of Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 is CH or C--R.sup.2, wherein at least two of Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 are CH.

5. The compound according to claim 1, wherein each R.sup.2 is the same or different and is independently halo or C.sub.1-3alkyl.

6. The compound according to claim 1 wherein each of Q.sup.1, Q.sup.2, and Q.sup.3 is CH and Q.sup.4 is C--F or C--Cl.

7. A compound of formula (I): ##STR00628## wherein: a is 0, 1, 2 or 3; each R.sup.1 is the same or different and is independently selected from halo, alkyl, haloalkyl, --OR.sup.6, --CO.sub.2R.sup.6, --NR.sup.6R.sup.7, and --CN; Ring A is selected from C.sub.3-6cycloalkyl, phenyl, 5-6 membered heterocycle and 5-6 membered heteroaryl, said heterocycle and said heteroaryl each having 1 or 2 heteroatoms selected from N, O and S; each of Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 is CH, C--R.sup.2 or N, wherein not more than one of Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 is N; each R.sup.2 is the same or different and is independently halo, alkyl, haloalkyl, or --OR.sup.6; W is --O-- or --S--; R.sup.3 is H, alkyl, haloalkyl, alkylene-OH, NR.sup.6R.sup.7, C.sub.3-6cycloalkyl, or Het; wherein said R.sup.3C.sub.3-6cycloalkyl is optionally substituted with 1 or 2 substituents which are the same or different and are independently selected from halo, C.sub.1-3alkyl, haloC.sub.1-3alkyl, OH, O--C.sub.1-3alkyl, oxo, S(C.sub.1-3alkyl), SO.sub.2, NH.sub.2, N(H)C.sub.1-3alkyl and N(C.sub.1-3alkyl).sub.2; Het is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N, O and S and optionally substituted with 1 or 2 substituents which are the same or different and are each independently selected from halo, C.sub.1-3alkyl, haloC.sub.1-3alkyl, O--C.sub.1-3alkyl, C.sub.1-3alkylene-O--C.sub.1-3alkyl, OH, C.sub.1-3alkylene-OH, oxo, SO.sub.2(C.sub.1-3alkyl), C.sub.1-3alkylene-SO.sub.2(C.sub.1-3alkyl), NH.sub.2, N(H)C.sub.1-3alkyl, N(C.sub.1-3alkyl).sub.2, CN, and --CH.sub.2CN; R.sup.4 is H, alkyl, haloalkyl, alkenyl, --OR.sup.6, --R.sup.5--OR.sup.6, --R.sup.5--CO.sub.2R.sup.6, --R.sup.5--SO.sub.2R.sup.6, --R.sup.5--Het, --N(H)R.sup.8, --N(CH.sub.3)R.sup.8, or --R.sup.5--NR.sup.6R.sup.7; each R.sup.5 is the same or different and is independently C.sub.1-4alkylene; each R.sup.6 and each R.sup.7 is the same or different and is independently H, alkyl or haloalkyl; and R.sup.8 is selected from H, alkyl, haloalkyl, C.sub.3-6cycloalkyl, --R.sup.5--C.sub.3-6cycloalkyl, Het.sup.2, --R.sup.5--Het.sup.2, --R.sup.5--OR.sup.6, --R.sup.5--O--R.sup.5--OR.sup.6, --R.sup.5--C(O).sub.2R.sup.6, --R.sup.5--C(O)NR.sup.6R.sup.7, --R.sup.5--N(H)C(O)--R.sup.6, --R.sup.5--N(H)C(O)--R.sup.5--OR.sup.6, --R.sup.5--N(H)C(O).sub.2--R.sup.6, --R.sup.5--NR.sup.6R.sup.7, --R.sup.5--S(O).sub.2R.sup.6, and --R.sup.5--N(H)S(O).sub.2R.sup.6; wherein said R.sup.8C.sub.3-6cycloalkyl is optionally substituted with 1 or 2 substituents which are the same or different and are independently selected from halo, C.sub.1-3alkyl, haloC.sub.1-3alkyl, OH, O--C.sub.1-3alkyl, oxo, S(C.sub.1-3alkyl), SO.sub.2(C.sub.1-3alkyl), NH.sub.2, N(H)C.sub.1-3alkyl and N(C.sub.1-3alkyl).sub.2, and N(H)SO.sub.2C.sub.1-3alkyl; and Het.sup.2 is a 4-6 membered heterocycle having 1 or 2 heteroatoms selected from N, O and S and optionally substituted with 1, 2, 3, 4 or 5 C.sub.1-3alkyl or 1 or 2 substituents which are the same or different and are each independently selected from halo, C.sub.1-3alkyl, haloC.sub.1-3alkyl, O--C.sub.1-3alkyl, C.sub.1-3alkylene-O--C.sub.1-3alkyl, OH, C.sub.1-3alkylene-OH, oxo, SO.sub.2(C.sub.1-3alkyl), C.sub.1-3alkylene-SO.sub.2(C.sub.1-3alkyl), NH.sub.2, N(H)C.sub.1-3alkyl, N(C.sub.1-3alkyl).sub.2, N(H)SO.sub.2C.sub.1-3alkyl, C(O)(C.sub.1-3alkyl), CO.sub.2(C.sub.1-4-alkyl), CN, and --CH.sub.2CN; or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 7, wherein the compound of formula (I) is a compound of formula (I-iii-a): ##STR00629## wherein Q.sup.4 is CH or C--R.sup.2.

9. The compound according to claim 7, wherein the compound of formula (I) is a compound of formula (I-iii-b): ##STR00630## wherein Q.sup.4 is CH or C--R.sup.2.

10. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

11. A method for treating melanoma in a human in need thereof, said method comprising administering to the human a therapeutically effective amount of a compound according to claim 1.

12. A process for preparing a compound according to claim 1, said process comprising reacting a compound of formula (VIII): ##STR00631## wherein R.sup.10 is halo or thiomethyl; with one of: i) molecular hydrogen ii) an alkyl metal reagent or alkenyl metal reagent iii) an alcohol, or iv) a compound of formula (IX): N(R.sup.a)--R.sup.8, wherein R.sup.a is H or CH.sub.3, to prepare a compound of formula (I).

13. A process for preparing a compound according to claim 1 comprising reacting a compound of formula (XVIII): ##STR00632## with a compound of formula (VII): ##STR00633## to prepare a compound of formula (I).

14. The method according to claim 11, wherein said melanoma is metastatic melanoma having a mutation encoding a V600E amino acid substitution.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc